Underestimation of cardiovascular risk by QRISK3 and RA-adapted SCORE2 in a Chinese rheumatoid arthritis population

Read full text
Authors: Xinpei Li, Xiaowei Ni, Wenjuan Qian, Chen Sun, Xiaoling Yuan, Yan Zhang, Yabing Zhang, Zening Yuan
Cited by: 0
References: 23

Abstract

Background: Patients with rheumatoid arthritis (RA) face a substantially increased risk of cardiovascular disease (CVD), yet existing risk prediction models often perform poorly in this population. QRISK3 and RA-adapted SCORE2 incorporate RA in their frameworks, but their validity in Asian cohorts remains uncertain. Methods: We conducted a retrospective observational study using electronic hospital records from The First People's Hospital of Zhangjiagang City in China (2020-2025). Adults with confirmed RA who subsequently experienced a first major CVD event (coronary heart disease, ischemic stroke, or transient ischemic attack) were included. QRISK3 and RA-adapted SCORE2 were applied to the conventional thresholds of ≥10% and ≥5% respectively, to define high risk. Agreement between tools was assessed with Cohen's kappa and McNemar's test. Adjusted logistic regression examined demographic, RA-related, and traditional risk factors associated with risk underestimation. Results: A total of 249 patients with RA and CVD were included. Both tools substantially underestimated risk, with underestimation more frequent for QRISK3 than RA-adapted SCORE2. Agreement between the two was moderate (κ = 0.44), with discordance most marked across age, glucocorticoid exposure, and disease activity subgroups. Patients with high baseline DAS28 scores were particularly likely to be misclassified as low risk. In adjusted models, diabetes, chronic kidney disease, and systemic steroid use were associated with greater underestimation. Conclusions: QRISK3 and RA-adapted SCORE2substantially underestimated cardiovascular risk in Chinese patients with RA, especially those with active disease. European-derived tools may not be reliable in this setting, underscoring the need for recalibrated or RA-specific models.

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Health Promotion and Cardiovascular Prevention Lipoproteins and Cardiovascular Health

Publication details

Journal / source
Frontiers in Cardiovascular Medicine
Volume
13
Pages
1712088–1712088
Publication date
12 February 2026
Language
EN